Adapting group sequential methods to observational postlicensure vaccine safety surveillance: Results of a pentavalent combination DTaP-IPV-Hib vaccine safety study

American Journal of Epidemiology

Volumn 177, Issue 2, 2013, Pages 131-141

  Nelson, Jennifer C ^a,b   Yu, Onchee ^a   Dominguez Islas, Clara P ^a,b   Cook, Andrea J ^a,b   Peterson, Do ^a   Greene, Sharon K ^c,d   Yih, W Katherine ^c,d   Daley, Matthew F ^g,h   Jacobsen, Steven J ⁱ   Klein, Nicola P ^e   Weintraub, Eric S ^f   Broder, Karen R ^f   Jackson, Lisa A ^a  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^e KAISER PERMANENTE   (United States)

^f NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^g Institute for Health Research   (United States)

^h University of Colorado Denver and Children s Hospital Colorado   (United States)

ⁱ Kaiser Permanente of Southern California ^*  (United States)

Author keywords

managed care programs; population surveillance; safety; sequential analysis; vaccines, combined

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

CHILD HEALTH; COHORT ANALYSIS; DATABASE; HEALTH RISK; POISSON RATIO; SPATIOTEMPORAL ANALYSIS; VACCINE;

ANAPHYLAXIS; ARTICLE; DIPHTHERIA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; FEVER; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HOSPITALIZATION; HUMAN; MENINGITIS; MYELITIS; PERTUSSIS; POLIOMYELITIS; SEIZURE; SIDE EFFECT; TETANUS;

CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT; MALE; MANAGED CARE PROGRAMS; ODDS RATIO; POISSON DISTRIBUTION; POLIOVIRUS VACCINE, INACTIVATED; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RISK; UNITED STATES; VACCINES, CONJUGATE;

HAEMOPHILUS INFLUENZAE SEROTYPE B; POLIOVIRUS;

EID: 84872247690     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws317     Document Type: Article

References (44)

1. Baciu A, Stratton KR, Burke SP. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press; 2007.
2. Congress of the United States. Food and Drug Administration Amendments Act of 2007. (Public Law 110-85, 110th Congress). Washington, DC: US GPO; 2008. (http://frwebgate. access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110-cong-public- laws&docid=f:publ085.110). (Accessed May 31, 2011).
3. Chen RT, DeStefano F, Davis RL, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ. 2000; 78(2):186-194.
4. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011;127(suppl 1):S45-S53.
5. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(10 suppl 2):S89-S95.
6. Klein NP, Fireman B, Yih W, et al. Measles-mumps-rubellavaricella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1-e8.
7. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine. 2009; 27(32):4257-4262.
8. Belongia EA, Irving S, Shui IM, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J. 2010;29(1):1-5.
9. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46): 8279-8284.
10. Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety using prospective weekly surveillance in the Vaccine Safety Datalink Project. Am J Prev Med. 2011;41(2):121-128.
11. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009; 27(34):4656-4661.
12. Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59(RR03):1-12.
13. Behrman RE, Benner JS, Brown JS, et al. Developing the Sentinel System-a national resource for evidence development. N Engl J Med. 2011;364(6):498-499.
14. Page ES. Continuous inspection schemes. Biometrika. 1954;41(1-2):100-115.
15. Wald A. Sequential tests of statistical hypotheses. Ann Math Stat. 1945;16(2):117-186.
16. Kulldorff M, Davis RL, Kolczak M, et al. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal. 2011;30(1):58-78.
17. Shih M-C, Lai TL, Heyse JF, et al. Sequential generalized likelihood ratio tests for vaccine safety evaluation. Stat Med. 2010;29(26):2698-2708.
18. Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011;127(suppl 1):S54-S64.
19. Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Stat Med. 2007; 26(28):5047-5080.
20. Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration. Pentacel Clinical Safety Review. Washington, DC: Food and Drug Administration; 2008. (http://www.fda.gov/ downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm125895.pdf). (Accessed July 11, 2011).
21. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and Haemophilus b conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep. 2008;57(39): 1079-1080.
22. Recommended immunization schedules for persons aged 0-18 years-United States, 2012. MMWR Morb Mortal Wkly Rep. 2012;61(5):1-4.
23. Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496-500.
24. Rennels MB. Combination vaccines. Pediatr Infect Dis J. 2002;21(3):255-257.
25. Freed GL, Cowan AE, Clark SJ, et al. Use of a new combined vaccine in pediatric practices. Pediatrics. 2006; 118(2):e251-e257.
26. Guerra FA, Blatter MM, Greenberg DP, et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics. 2009;123(1):301-312.
27. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussisdiphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age. Vaccine. 1998;16(6):576-585.
28. Scheifele DW, Halperin SA, Rubin E, et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age. Hum Vaccine. 2005;1(5):180-186.
29. Gold R, Barreto L, Ferro S, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussisdiphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol. 2007;18(4):241-248.
30. Bernstein HH, Noriega F. Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: a randomized, open-label, phase 3 study. Vaccine. 2011;29(11):2212-2221.
31. Continued shortage of Haemophilus influenzae type b (Hib) conjugate vaccines and potential implications for Hib surveillance-United States, 2008. MMWR Morb Mortal Wkly Rep. 2008;57(46):1252-1255.
32. Invasive Haemophilus influenzae type B disease in five young children-Minnesota, 2008. MMWR Morb Mortal Wkly Rep. 2008;58(3):58-60.
33. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191-199.
34. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics. 1987; 43(1):193-199.
35. Kittleson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics. 1999;55(3):874-882.
36. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Revised 2nd ed. Chichester, United Kingdom: John Wiley & Sons Ltd; 2000:135-181.
37. Nelson JC, Cook AJ, Yu O, et al. Methods for observational post-licensure medical product safety surveillance [published online ahead of print December 2, 2011]. Stat Methods Med Res. (doi:10.1177/0962280211413452).
38. Nelson JC, Cook AJ, Yu O, et al. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1): 62-71.
39. Kulldorff M. Sequential statistical methods for prospective post-marketing safety surveillance. In: Strom BL, Kimmel SE, Hennessy S, eds. Pharmacoepidemiology. 5th ed. Sussex, United Kingdom: John Wiley & Sons Ltd; 2011.
40. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007;16(12):1275-1284.
41. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-556.
42. Zhao S, Cook AJ, Jackson LA, et al. Statistical performance of group sequential methods for observational post-licensure medical product safety surveillance: a simulation study. Stat Interface. 2012;5:381-390.
43. Greene SK, Kulldorff M, Yin R, et al. Near real-time vaccine safety surveillance with partially accrued data. Pharmacoepidemiol Drug Saf. 2011;20(6):583-590.
44. WHO Collaborating Centre for International Drug Monitoring. Report From the WHO Collaborating Centre for International Drug Monitoring: Activities July 2008-June 2009. Geneva, Switzerland: World Health Organization; 2009. (http://www.who-umc.org/graphics/21411.pdf). (Accessed November 11, 2011).